Risk Management To Drive Toughened CDRH Compliance Approach
This article was originally published in The Silver Sheet
Executive Summary
FDA DEVICE ENFORCEMENT ACTIVITIES will focus on companies that fail to ensure strict QS regulatory compliance at subsidiaries, with Office of Compliance Director Timothy Ulatowski warning of upcoming corporate-wide legal actions. Companies marked by a series of poor inspections are particularly likely to be targeted amidst an enforcement climate that top FDA officials and outside observers alike describe as increasingly aggressive. To gain information about the most serious violations at device firms, OC is transitioning to a risk-based inspection agenda and new systems for analyzing recalls, MDRs and MedSun reports. Also on the enforcement chief’s front burner: a crackdown on misleading promotions and ads
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.